New research out of Tel Aviv University found that the South African variant, as they are calling it, is primarily showing up in people who have already been injected with the messenger RNA (mRNA) gene therapy syringe from Pfizer and BioNTech.
The study, which has not yet been peer-reviewed, indicates that the B.1.351 variant of Chinese germs is eight times more prevalent in people who were injected – 5.4 percent compared to 0.7 percent – versus people who are just saying no to the jab.
“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group,” said Adi Stern from the school. “This means that the South African variant is able, to some extent, to break through the vaccine’s protection.”
The study looked at 400 people who had received at least one shot of the Pfizer-BioNTech injection and who had also contracted a Kung Flu variant. This group was then compared to the same number of people who had become infected but were not injected with any chemicals for Chinese germs.
“It is the first in the world to be based on real-world data, showing that the vaccine is less effective against the South Africa variant, compared to both the original virus and the British variant,” stated Prof. Ran Balicer, director of research at Clalit Health Services, which also contributed to the study....<<<Read The Full Article Here>>>...
